Vernal Biosciences has received $21 million from investors and is expanding to a new laboratory in Essex next year.
Vernal Biosciences has raised $21 million to build a manufacturing facility in Essex that will scale up the business from supporting research to being involved in clinical trials.
Vernal Biosciences announced today the completion of a $21 million financing to fully integrate its mRNA manufacturing solutions.
We are excited to announce the addition of two new members to the Vernal team: Scott Vanson, Ph.D. and JJ Bivona, Ph.D.
Vernal Biosciences has been awarded a $99,475 grant from the Vermont Training Program (VTP).
We recently completed a biodistribution study of lipid nanoparticles containing mRNA encoding luciferase in mice.
Vernal Biosciences, the Colchester-based manufacturer of mRNA used in cutting-edge medicines, plans to nearly triple the size of its staff, from 12 to 35, using a grant from the Vermont Training Program. Read the full story here.
Vernal Biosciences in Colchester helps make mRNA, which acts as a kind of roadmap a cell uses to make a specific protein.
Vernal Biosciences, a startup based in Colchester, is manufacturing mRNA for a range of pharmaceutical companies doing more than making vaccines. Read the full story here.
Christian Cobaugh, CEO of Vernal Biosciences in Colchester, explains how his company makes DNA and why it’s important for making mRNA. Read the full story here.
Five years ago, when Christian Cobaugh had the idea of starting a biotech company to manufacture mRNA, the genetic term wasn't in the vernacular of most nonscientists.
We announced the closing of a seed round of financing today.